^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    dapansutrile (OLT1177)

    i
    Other names: OLT1177, OLT-1177
    Associations

    News

    Trials
    Company:
    Olatec Therap
    Drug class:
    NLRP3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    DAPA-PD: A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Cambridge University Hospitals NHS Foundation Trust
    New P2 trial
    |
    dapansutrile (OLT1177)
    6ms
    Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, University of Virginia | Trial completion date: Oct 2028 --> Jan 2029 | Trial primary completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    dapansutrile (OLT1177)
    6ms
    Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare (clinicaltrials.gov)
    P2/3, N=300, Recruiting, Olatec Therapeutics LLC | Trial completion date: Oct 2025 --> Dec 2025
    Trial completion date
    |
    dapansutrile (OLT1177)
    over1year
    Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare (clinicaltrials.gov)
    P2/3, N=300, Recruiting, Olatec Therapeutics LLC | Trial completion date: Dec 2025 --> Oct 2025 | Trial primary completion date: Nov 2025 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    dapansutrile (OLT1177)
    over1year
    Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare (clinicaltrials.gov)
    P2/3, N=300, Recruiting, Olatec Therapeutics LLC | Trial completion date: Oct 2024 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    dapansutrile (OLT1177)
    over1year
    Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia (clinicaltrials.gov)
    P2, N=300, Recruiting, University Hospital, Basel, Switzerland | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CRP (C-reactive protein)
    |
    dapansutrile (OLT1177)
    over1year
    A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=26, Recruiting, April Salama, M.D. | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • dapansutrile (OLT1177)
    over1year
    Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, University Hospital, Basel, Switzerland | Initiation date: Nov 2023 --> Apr 2024
    Trial initiation date
    |
    CRP (C-reactive protein)
    |
    dapansutrile (OLT1177)
    almost2years
    Systemic inflammatory cytokine profiles in patients with gout during flare, intercritical and treat-to-target phases: TNFSF14 as new biomarker. (PubMed, Ann Rheum Dis)
    Gout flare involves multiple inflammatory mediators that may be used as potential therapeutic targets.
    Journal
    |
    IL6 (Interleukin 6) • CSF1 (Colony stimulating factor 1) • TNFSF14 (TNF Superfamily Member 14)
    |
    dapansutrile (OLT1177)
    almost2years
    Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome (clinicaltrials.gov)
    P2, N=2, Terminated, Olatec Therapeutics LLC | N=10 --> 2 | Recruiting --> Terminated; The study was terminated due to study design issues that did not allow for determination of efficacy and safety in subjects with Schnitzler Syndrome who are currently well controlled on anakinra therapy.
    Enrollment change • Trial termination
    |
    dapansutrile (OLT1177)
    almost2years
    The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production. (PubMed, Biomolecules)
    This was confirmed using an NLRP3 inhibitor, OLT1177, which revealed a similar beneficial effect in combating TNBC progression. Sch B treatment also inhibits IL-1β-induced EMT expression of TNBC cells, which may contribute to the anti-tumor response.
    Journal • IO biomarker
    |
    IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    dapansutrile (OLT1177)